PMID- 26875756
OWN - NLM
STAT- MEDLINE
DCOM- 20170210
LR  - 20220318
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 233
IP  - 10
DP  - 2016 May
TI  - Delta(9)-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice 
      and rats.
PG  - 1901-10
LID - 10.1007/s00213-016-4237-6 [doi]
AB  - RATIONALE: Novel cannabinoid compounds continue to be marketed as "legal" 
      marijuana substitutes, even though little is known about their molecular and 
      behavioral effects. OBJECTIVES: Six of these compounds (ADBICA, ADB-PINACA, 
      THJ-2201, RCS-4, JWH-122, JWH-210) were tested for in vitro and in vivo 
      cannabinoid-like effects to determine their abuse liability. METHODS: Binding to 
      and functional activity at CB1 cannabinoid receptors was tested. Locomotor 
      activity in mice was tested to screen for behavioral activity and to identify 
      behaviorally active dose ranges and times of peak effect. Discriminative stimulus 
      effects of the six compounds were tested in rats trained to discriminate 
      Delta(9)-tetrahydrocannabinol (Delta(9)-THC). RESULTS: ADBICA, ADB-PINACA, THJ-2201, 
      RCS-4, JWH-122, and JWH-210 showed high affinity binding at the CB1 receptor at 
      nanomolar affinities (0.59 to 22.5 nM), and all acted as full agonists with 
      nanomolar potencies (0.024 to 111 nM) when compared to the CB1 receptor full 
      agonist CP 55940. All compounds depressed locomotor activity below 50 % of 
      vehicle responding, with depressant effects lasting 1.5 to nearly 4 h. All 
      compounds fully substituted (<80 % Delta(9)-THC-appropriate responding) for the 
      discriminative stimulus effects of Delta(9)-THC. 3,4-Methylenedioxy-methamphetamine 
      (MDMA) was tested as a negative control and did not substitute for Delta(9)-THC (11 % 
      Delta(9)-THC-appropriate responding). CONCLUSIONS: All six of the compounds acted at 
      the CB1 receptor and produced behavioral effects common to abused cannabinoid 
      compounds, which suggest that these compounds have substantial abuse liability 
      common to controlled synthetic cannabinoid compounds.
FAU - Gatch, Michael B
AU  - Gatch MB
AD  - Department of Pharmacology and Neuroscience, University of North Texas Health 
      Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76107-2699, USA. 
      michael.gatch@unthsc.edu.
FAU - Forster, Michael J
AU  - Forster MJ
AD  - Department of Pharmacology and Neuroscience, University of North Texas Health 
      Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76107-2699, USA.
LA  - eng
GR  - HHSN271201300001C/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160215
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Cannabinoids)
RN  - 0 (Receptor, Cannabinoid, CB1)
RN  - 7J8897W37S (Dronabinol)
SB  - IM
MH  - Animals
MH  - CHO Cells
MH  - Cannabinoids/*pharmacology
MH  - Cricetulus
MH  - Dose-Response Relationship, Drug
MH  - Dronabinol/*pharmacology
MH  - Locomotion/drug effects
MH  - Male
MH  - Mice
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptor, Cannabinoid, CB1/metabolism
MH  - Substance-Related Disorders/etiology/metabolism
PMC - PMC4846470
MID - NIHMS760394
OTO - NOTNLM
OT  - Abuse liability
OT  - Cannabinoids
OT  - Drug discrimination
OT  - Locomotor activity
OT  - Mouse
OT  - Rat
EDAT- 2016/02/16 06:00
MHDA- 2017/02/12 06:00
PMCR- 2017/05/01
CRDT- 2016/02/16 06:00
PHST- 2015/12/09 00:00 [received]
PHST- 2016/02/03 00:00 [accepted]
PHST- 2016/02/16 06:00 [entrez]
PHST- 2016/02/16 06:00 [pubmed]
PHST- 2017/02/12 06:00 [medline]
PHST- 2017/05/01 00:00 [pmc-release]
AID - 10.1007/s00213-016-4237-6 [pii]
AID - 10.1007/s00213-016-4237-6 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2016 May;233(10):1901-10. doi: 
      10.1007/s00213-016-4237-6. Epub 2016 Feb 15.